

Novel method to remove bilirubin from the blood of jaundiced rats: a preliminary study

Jie Hao

The First Affiliated Hospital of Xi'an Jiaotong University

Li-Fei Yang

The First Affiliated Hospital of Xi'an Jiaotong University

Yong Wan

The First Affiliated Hospital of Xi'an Jiaotong University

Jia-Wei Yu

The First Affiliated Hospital of Xi'an Jiaotong University

Lu Ren

The First Affiliated Hospital of Xi'an Jiaotong University

Xu-Feng Zhang

The First Affiliated Hospital of Xi'an Jiaotong University

Yi Lv

The First Affiliated Hospital of Xi'an Jiaotong University

Qiang Lu (✉ thesurgeon@163.com)

The First Affiliated Hospital of Xi'an Jiaotong University

Hong-Fan Ding

The First Affiliated Hospital of Xi'an Jiaotong University

Research Article

Keywords: Novel treatment, Jaundice, Hyperbilirubinemia, Cross circulation

Posted Date: June 3rd, 2022

DOI: <https://doi.org/10.21203/rs.3.rs-1035823/v2>

License:   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

BACKGROUND

The removal of bilirubin from serum is the primary method for treating hyperbilirubinemia. However, currently used treatment methods have several limitations. This study was designed to introduce a novel method to remove bilirubin from the blood of jaundiced rats.

METHODS

This novel therapy involved cross-circulation of blood between a rat liver preserved in vitro and a rat with hyperbilirubinemia. All model animals were randomly divided into two groups based on whether they received the novel therapy. Serum samples were collected at different time points. The levels of serum transaminase and bilirubin were detected and compared between different groups. Long-term survival was compared by Kaplan-Meier analysis between different groups.

RESULTS

Across different hyperbilirubinemia models, serum total bilirubin level was significantly improved (24.8 ± 1.2 vs. 17.4 ± 1.2 $\mu\text{mol/L}$, $P < 0.05$), despite a rise serum transaminase levels after treatment (AST: 4612 ± 382 vs. 5144 ± 390 U/L, $P > 0.05$; ALT: 5051 ± 722 vs. 5488 ± 707 U/L, $P < 0.05$). No necrosis was found in the preserved liver tissue after treatment. This novel treatment significantly raised the long-term survival rates of jaundiced rats ($P < 0.05$).

CONCLUSION

This novel method could safely and effectively help eliminate bilirubin from the blood of jaundiced rats.

Introduction

Jaundice is the primary symptom of severe liver disease that affects the ability of the liver to metabolise and secrete bilirubin[1, 2]. Bilirubin is a cytotoxic substance that can cause mitochondrial dysfunction, lead to organ system dysfunction, and even endanger life[3–6]. Currently, there are several limitations to jaundice treatment, especially for jaundice caused by liver failure, as existing liver replacement therapy cannot emulate the full physiological function of the liver[7–9]. In recent years, it has been proven that the liver can be preserved using machine perfusion to maintain a physiological milieu. Therefore, this study was designed to verify whether a novel therapy involving cross-circulation between the liver preserved in vitro and the jaundiced rat can be effective.

Materials And Methods

Novel therapy procedure

This novel therapy is designed to stimulate cross-circulation between a liver preserved in vitro and a jaundiced rat (Fig. 1). First, the jaundiced model rat underwent carotid and jugular vein catheterisation using an anticoagulant catheter after anaesthesia. Next, a donor's liver was harvested after 30% partial hepatectomy, and superior-inferior vena cava ligation and biliary intubation were performed. The donor's liver was then preserved in normal saline at 4 °C. Third, blood flow was restored by connecting the carotid artery and jugular vein cannulas to the portal vein and the infrahepatic inferior vena cava of the donor's liver (Fig. 2).

Animals

Forty 6-week-old Sprague-Dawley rats, weighing 230–250 g, housed under a 12-h daylight/darkness cycle and in an air-conditioned animal room with 50% humidity, were obtained from the Experimental Animal Center of Xi'an Jiaotong University. These rats were jaundiced due to acute liver failure induced by D-galactosamine. They were randomised into two groups according to the therapy administered: group T (therapy, n = 20), rats in this group received the novel therapy; group C (control, n = 20), rats in this group did not receive any therapy, but underwent carotid artery and jugular vein cannulation. Another 20 rats were used as donors and underwent partial 50% hepatectomy before their livers were harvested. Buprenorphine (0.05 mg/kg) was injected subcutaneously as an analgesic 1 hour before the operation. All the rats were anaesthetised, with 5% vol isoflurane at a flow rate of 1.5 L/min in a Plexiglas box used to induce anaesthesia and 2% vol isoflurane at a flow rate of 0.6–0.8 L/min in a cone mask for the maintenance of anaesthesia. All rats were heparinised by injecting 20 U of heparin diluted in 2 ml of normal saline solution through the dorsal vein of the penis before treatment. This study was performed according to the Guide for the Care and Use of Laboratory Animals published by the National Academy of Sciences. The study design was approved by the Committee on the Ethics of Animal Experiments of Xi'an Jiaotong University (Permit Number 2010 – 105).

Animal model

All the rats in group T and group C received an intraperitoneal injection of 1.1 g/kg of D(+)-galactosamine hydrochloride (Sigma Chemical Corporation, St Louis, Missouri, USA) as a 100 mg/ml solution (pH 6.8) in normal saline[10] 48 hours before receiving the novel therapy.

Liver function tests

Liver function tests, including serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), and total bilirubin (TBIL) levels were performed before modelling, at the beginning of treatment in group T (ending of cannulation in group C), and 2 hours after treatment in group T (2 hours after cannulation in group C). Rats used for survival analysis were observed for 48 hours after treatment.

Histological analysis

After treatment, in vitro liver tissue was obtained and fixed in 10% buffered formalin overnight before embedding in paraffin. Liver sections were cut to 4- μ m thick and stained with haematoxylin and eosin.

Statistical analysis

Numerical data were expressed as a mean \pm SEM (Standard Error of Mean) and compared using the Student's *t*-test or Mann–Whitney U test. All data were analysed using Prism 6 (GraphPad Software Inc., CA, USA). Overall survival was estimated by the Kaplan-Meier method, and differences between groups were compared via the log-rank test, using IBM SPSS Statistics ver. 22.0 (IBM Co., Armonk, NY, USA). A *P*-value less than 0.05 was considered statistically significant. A biomedical statistician reviewed the study data for statistical correctness.

Results

Animal model

A drug-induced liver failure model in rats was successfully established in this study. In group T, serum AST, ALT, and bilirubin levels increased significantly 24 hours after modelling (AST: 97 ± 2 vs. 4612 ± 382 U/L, *P*<0.05; ALT: 96 ± 3 vs. 5051 ± 722 U/L, *P*<0.05; TBIL: 9.7 ± 0.4 vs. 24.8 ± 1.2 mmol/L, *P*<0.05; see Fig. 4A-C). The trend of serum bilirubin level change in group C was similar to that in group T (AST: 98 ± 3 vs. 4747 ± 527 U/L, *P*<0.05; ALT: 96 ± 3 vs. 4369 ± 390 U/L, *P*<0.05; TBIL: 10.0 ± 0.3 vs. 24.9 ± 1.3 mmol/L, *P*<0.05; see Fig. 4D-F).

Therapy

All the jaundiced rats were treated successfully, and no rats died during the treatment. The donor liver was perfused well after restoring blood flow, and no ischaemic lesions were found (Fig. 3A). Catheter obstruction was not observed during the experiment. The donor liver produced bile during the treatment, and the colour of bile during treatment was darker than that during harvesting (Fig. 3B).

Liver function test and histological findings

Serum bilirubin concentration in group T decreased significantly after the treatment (24.8 ± 1.2 vs. 17.4 ± 1.2 μ mol/L, *P*<0.05, see Fig. 4C). However, serum AST and ALT levels were elevated after treatment (AST: 4612 ± 382 vs. 5144 ± 390 U/L, *P*>0.05; ALT: 5051 ± 722 vs. 5488 ± 707 U/L, *P*<0.05, see Fig. 4A-B). The serum AST, ALT, and bilirubin levels of rats in group T continued to rise after cannulation (TBIL: 24.9 ± 1.3 vs. 26.0 ± 1.3 mmol/L, *P*>0.05; AST: 4747 ± 527 vs. 5466 ± 591 U/L, *P*>0.05; ALT: 4369 ± 390 vs. 5093 ± 380 U/L, *P*>0.05, see Fig. 4D-F). After treatment, the hepatic lobule structure of the liver in vitro was normal, and hepatocyte necrosis was not observed on histological examination (Fig. 5).

Survival

The survival curves for both groups are shown in Fig. 6. Overall, the survival rate of rats in group T was higher than that in group C within the 48 hours after therapy, and there was a significant statistical difference between the two groups (*P* = 0.012).

Discussion

This study details a novel therapeutic strategy for bilirubin elimination from the blood of animal models. This therapy may help improve the prognosis of patients with jaundice.

There are several theoretical pathophysiological approaches to filter serum bilirubin in cases of liver failure. One approach would be to increase liver regeneration or perform liver transplantation. Unfortunately, the current supply of acceptable donor livers is not adequate to meet the high demands of listed patients awaiting transplantation, resulting in thousands of deaths each year. An extracorporeal system is another promising feasible approach to liver support. However, evidence suggests that the sole use of liver support systems to remove bilirubin is not adequate to improve survival in patients with liver failure[7, 11–13] because these systems can only partially replace the physiological function of the liver.

In this study, we proposed a novel therapy to eliminate bilirubin from serum. A liver preserved in vitro was perfused with the blood of a jaundiced rat through cross-circulation. As the carotid artery pressure is higher than that of the jugular and portal veins, studies suggested that if the liver was perfused with the blood at a higher pressure, it might disturb the microcirculation and increase the rate of hepatocellular apoptosis[14–16]. However, no obvious hepatocyte apoptosis was detected on histological examination of the liver in vitro after treatment. This might have been because the pressure of the arterial blood significantly decreased after passing through the catheter. In addition, the liver was well perfused during the treatment and was able to produce bile, indicating that the liver can play a role in detoxification and secretion in vitro.

Cross-circulation between two humans has been found to be effective for treating uraemia, treatment of liver failure, provision of large numbers of leukocytes, and cardiopulmonary bypass during cardiac surgery[17–21]. However, it appears that chance selection of a donor and recipient of divergent histocompatibility might result in severe and even potentially fatal outcomes, such as immunologic complications, disease transmission, and compromised donor safety. In this study, cross-circulation was developed between the organ preserved in vitro and the recipient, which might have helped avoid the above problems. In addition to a significant decrease in serum bilirubin, our method also helped reduce 48h survival of the jaundiced rats. Unlike other therapies for removing bilirubin from serum, this therapy could compensate for all liver functions; this might be the main reason for improved 48h prognosis in model rats.

Although the results of this study are encouraging, several limitations should also be considered. First, this study only proved that this novel treatment could reduce the serum bilirubin level of an individual with hyperbilirubinemia and improve the long-term survival in an animal model. The effect of this treatment on coagulation function and other toxic substances in serum remains unclear. In addition, this study only verified the feasibility and effectiveness of the novel treatment method in the rat; thus, further exploration is needed in larger mammals.

List Of Abbreviations

AST, aspartate aminotransferase

ALT, alanine aminotransferase

TBIL, and total bilirubin

Declarations

Ethics approval: This study was performed according to the Guide for the Care and Use of Laboratory Animals published by the National Academy of Sciences, and the study design was reviewed and approved by the Committee on the Ethics of Animal Experiments of Xi'an Jiaotong University (Permit Number 2020-105). The study was carried out in compliance with the ARRIVE guidelines.

Consent for publication: Not applicable

Availability of data and materials: The datasets used and analysed during the current study are available from the corresponding author on reasonable request.

Competing interests: The authors declare that they have no competing interests

Funding: This study was supported by the Shaanxi Province Key R&D Plan University Joint Project-Key Project (2021GXLH-Z-047) and Natural Science Basic Research Program of Shaanxi (Program No. 2020JQ-528).

Authors' contributions: Hao J. and Lu Q. designed the study; Lu Q., Ding H.F., Yang L.F., Wan Y. and Ren L. performed the research and acquired the data; Lu Q., Yang L.F. and Yu J.W. analyzed the data; Lu Q. and Zhang X.F. drafted the manuscript; Lv Y. and Lu Q. contributed significantly to the revision of the manuscript.

Acknowledgements: Not applicable.

References

1. Ji S, DC R: **Diagnosis and evaluation of hyperbilirubinemia.** *Current opinion in gastroenterology* 2017, **33**(3):164–170.
2. E S, M J: **New insights in bilirubin metabolism and their clinical implications.** *World journal of gastroenterology* 2013, **19**(38):6398–6407.
3. R W: **Bilirubin transport and toxicity.** *Mead Johnson Symposium on Perinatal and Developmental Medicine* 1982(19):25–31.
4. J F: **Bilirubin in clinical practice: a review.** *Liver international: official journal of the International Association for the Study of the Liver* 2008, **28**(5):592–605.
5. MM O, O F, H N, MR A, N A, HR M, M H, K M, S A, A J *et al.* **Cholestasis-associated reproductive toxicity in male and female rats: The fundamental role of mitochondrial impairment and oxidative stress.** *Toxicology letters* 2019, **316**:60–72.

6. M AB, RF S, D B: **Bilirubin toxicity to human erythrocytes: a review.** Clinica chimica acta; international journal of clinical chemistry 2006, **374**:46–56.
7. García Martínez JJ, Bendjelid K: **Artificial liver support systems: what is new over the last decade?** Annals of intensive care 2018, **8**(1):109.
8. Gonzalez HC, Jafri SM, Gordon SC: **Management of Acute Hepatotoxicity Including Medical Agents and Liver Support Systems.** Clinics in liver disease 2017, **21**(1):163–180.
9. Wang DW, Yin YM, Yao YM: **Advances in the management of acute liver failure.** World J Gastroenterol 2013, **19**(41):7069–7077.
10. E C, C L, TM C: **Biochemical, hematological and histological changes in a fulminant hepatic failure rat model for artificial liver assessment.** Artificial organs 1979, **3**(1):42–46.
11. Palmes D, Qayumi AK, Spiegel HU: **Liver bridging techniques in the treatment of acute liver failure.** Journal of investigative surgery: the official journal of the Academy of Surgical Research 2000, **13**(6):299–311.
12. Rajvanshi P, Larson AM, Kowdley KV: **Temporary support for acute liver failure.** Journal of clinical gastroenterology 2002, **35**(4):335–344.
13. Larsen FS: **Artificial liver support in acute and acute-on-chronic liver failure.** Curr Opin Crit Care 2019, **25**(2):187–191.
14. K S, DL S, HU K, S T, R A, C G, T G, AH H, KT B: **Portal hyperperfusion causes disturbance of microcirculation and increased rate of hepatocellular apoptosis: investigations in heterotopic rat liver transplantation with portal vein arterialization.** *Transplantation proceedings* 2006, **38**(3):725–729.
15. YF C, TL H, TY C, A C, LL T, CC W, SH W, CK S, CC L, YW L *et al*: **Liver graft-to-recipient spleen size ratio as a novel predictor of portal hyperperfusion syndrome in living donor liver transplantation.** American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2006, **6**(12):2994–2999.
16. M S, M C, A C, AD P: **Liver function impairment in liver transplantation and after extended hepatectomy.** World journal of gastroenterology 2013, **19**(44):7922–7929.
17. Di Donna D: **[Cross transfusion in therapy of anuria].** Minerva medica 1952, **43**(82):640–641.
18. Burnell JM, Thomas ED, Ansell JS, Cross HE, Dillard DH, Epstein RB, Eschbach JW, Jr., Hogan R, Hutchings RH, Motulsky A *et al*: **OBSERVATIONS ON CROSS CIRCULATION IN MAN.** The American journal of medicine 1965, **38**:832–841.
19. Salisbury PF, Bolomey AA, Miller JH: **Cross transfusion. III. clinical experiences with 6 cases.** The American journal of the medical sciences 1952, **223**(2):151–167.
20. Bierman HR, Byron RL, Jr., Kelly KH, Dod KS, Black PM: **Studies on cross circulation in man. I. Methods and clinical changes.** Blood 1951, **6**(6):487–503.
21. Warden HE, Cohen M, Read RC, Lillehei CW: **Controlled cross circulation for open intracardiac surgery: physiologic studies and results of creation and closure of ventricular septal defects.** The Journal of thoracic surgery 1954, **28**(3):331–341; discussion, 341 – 333.

Figures




Figure 1

Schematic diagram of the novel treatment method.




Figure 2

The novel method for the treatment of hyperbilirubinemia. A: The liver was perfused with arterial blood from model animals via the portal vein. The blood then flowed back to the jugular vein of the model animal through the inferior vena cava. The liver was well perfused and produced bile; B: Carotid and jugular vein catheterization was performed using an anticoagulant catheter.






Figure 3


A: The liver preserved in vitro; B: The bile produced during harvesting (*) and treatment (#).




(a)




(b)




(c)



(d)



(e)



(f)

Figure 4

Changes of serum AST, ALT, and TBIL levels in the model animal.




Figure 5

Histological examination of the liver in vitro after treatment.




Figure 6

48-hour survival of rats in different groups